Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics Q1 net loss narrows to $10.0 million; cash runway into 2029

Positive Impact 3 of 5 earnings Written later

AN2 Therapeutics reported a first-quarter 2026 net loss of $10.0 million, down from $10.6 million a year earlier, as research and development expenses fell to $6.7 million from $7.7 million. The company had $85.3 million in cash, cash equivalents and investments at March 31, 2026, after a $40.0 million private placement in March, and it projects that funding will sustain operations into 2029.

Key points

  • Net loss of $10.0 million for Q1 2026, compared with $10.6 million in Q1 2025
  • R&D expenses of $6.7 million, down from $7.7 million, driven by lower chemistry manufacturing and controls costs
  • Cash, cash equivalents and investments of $85.3 million at March 31, 2026, after a $40.0 million private placement in March 2026
  • Interest income fell to $0.5 million from $0.9 million on lower cash balances and interest rates

The filing

CompanyAN2 Therapeutics, Inc. (ANTX)
Form8-K, current report
Filed with the SECMay 11, 2026, 4:06 PM ET
Accession number0001193125-26-216752

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.